Sanofi 'weighs €200m sale of older drug products'  

Sanofi has reached out to potential private equity and strategic buyers but the drugs being sold are not part of Sanofi’s fast-growing immunology franchise.

Sanofi is weighing a sale of some of its older anti-inflammatory products, according to people familiar with the matter, as it swivels toward innovative new therapies.

The French drugmaker is studying options for the assets, the sources said, including several mature inflammation treatments and could fetch as much as €200m.